[Kaposi's sarkoma in solid organ recipients].

Area of Science:

• Oncology
• Virology
• Immunology

Context:

• Kaposi's sarcoma (KS) is an angio-proliferative malignancy often associated with human Herpesvirus 8 (HHV-8).
• While typically presenting as skin lesions, KS can involve visceral organs, though this is rare as an isolated form.
• KS incidence is low in the general population but significantly higher in immunocompromised individuals, including organ transplant recipients on immunosuppressive therapy.

Purpose:

• To explore the relationship between immunosuppression intensity and the risk of developing Kaposi's sarcoma post-transplantation.
• To review current treatment strategies for Kaposi's sarcoma, differentiating between localized and widespread disease.
• To evaluate the therapeutic efficacy of modifying immunosuppression regimens in transplant recipients with Kaposi's sarcoma.

Summary:

• Kaposi's sarcoma (KS) development risk in transplant recipients correlates strongly with the potency of immunosuppression.
• Localized KS is treatable with local therapies (surgery, cryotherapy, radiotherapy), whereas widespread disease requires systemic treatment.
• Reducing or halting immunosuppression, particularly calcineurin inhibitors, yields positive outcomes. Switching to rapamycin, an immunosuppressant with anti-neoplastic properties, presents a novel therapeutic avenue for solid organ recipients.

Impact:

• Highlights the critical role of immunosuppression management in preventing and treating Kaposi's sarcoma in transplant patients.
• Identifies rapamycin as a promising alternative immunosuppressive agent with potential anti-cancer activity for solid organ transplant recipients.
• Informs clinical practice regarding risk stratification and therapeutic interventions for Kaposi's sarcoma in immunocompromised populations.